FTC Drops AndroGel Antitrust Case Against AbbVie
The Federal Trade Commission is dropping its long-running case accusing AbbVie of illegally delaying generic versions of the testosterone treatment AndroGel, saying Friday the case shows enforcers need new legislation to...To view the full article, register now.
Already a subscriber? Click here to view full article